# Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus

> **NCT01226043** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 405 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT01226043
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2013-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01226043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01226043, "Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01226043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*